Dapagliflozin lowers HbA1c in pediatric T2D

      According to the phase III T2NOW trial, Dapagliflozin remarkably reduces HbA1c by 1.03 % in children and adolescents with type 2 diabetes, compared to Saxagliptin. T2NOW trail spanned 26 weeks, with a 26-week extension, and enrolled participants aged 10 to 17 years with uncontrolled type 2 diabetes and who were already undergoing treatment with metformin, insulin, or both medications. The trial exhibited statistically significant results for both primary and secondary endpoints, highlighting the role of Dapagliflozin in effectively managing glycaemia in children and adolescents with type 2 diabetes. Furthermore, the safety outcomes observed in the pediatric cohort were consistent with the established safety profile of Dapagliflozin in adults with T2D.

      The researchers noted that the significant decrease in HbA1C levels achieved with Dapagliflozin could signify a reduction in disease progression and its associated complications. The finding emphasizes the promising role of Dapagliflozin in addressing the specific needs of younger patients with T2D, providing them with an effective treatment option for managing their condition.